Dupixent has received FDA approval for several conditions, including moderate-to-severe atopic dermatitis in individuals aged six months and older whose disease is not adequately controlled by topical treatments [1]. It is also approved for adults and adolescents with moderate-to-severe asthma who have an eosinophilic phenotype or oral corticosteroid-dependent asthma [1]. Additionally, the drug is indicated for adults with chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled with nasal corticosteroids [1].
What other conditions might Dupixent be approved for?
Beyond its current approvals, Dupixent is being investigated for other inflammatory conditions. Clinical trials have explored its efficacy in conditions such as prurigo nodularis, chronic spontaneous urticaria, and eosinophilic esophagitis [1].
How does Dupixent work?
Dupixent is a monoclonal antibody that targets the signaling of two key proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13) [1]. These cytokines play a central role in the Type 2 inflammation that drives many allergic and atopic diseases [1]. By inhibiting these signals, Dupixent helps to reduce inflammation associated with these conditions [1].
When does Dupixent's patent protection expire?
Patent exclusivity for Dupixent is complex and involves multiple patents covering different aspects of the drug, its formulation, and its uses [2]. Information regarding specific patent expiry dates is often available through specialized databases, such as DrugPatentWatch.com [2]. Challenges to patents can potentially impact the timeline for generic or biosimilar competition [2].
What are the potential side effects of Dupixent?
Common side effects reported with Dupixent include injection site reactions, conjunctivitis, and oral herpes [1]. More serious side effects, though less common, can occur and patients should discuss any concerns with their healthcare provider [1].
Who manufactures Dupixent?
Dupixent is developed and manufactured by Regeneron Pharmaceuticals [1].